Archive · 7 Sep 2026
MedGenome Launches Blood Test to Detect Residual Cancer
MedGenome has introduced a blood test called OncoTrack MRD for people who have already been treated for cancer.
It looks for tiny pieces of cancer DNA in the blood.
First, doctors use the person’s tumour and blood to create a special genetic fingerprint.
Later tests only need a blood sample to look for that fingerprint.
The test is meant for cancers such as breast, colorectal, lung, ovarian and pancreatic cancer.
It may find signs of cancer earlier than scans can detect a larger tumour.
However, a positive result does not prove that cancer will return, and a negative result does not guarantee that it will not.
Doctors must consider the result together with scans, cancer type, stage and treatment history.
MedGenome launched OncoTrack MRD, a personalised blood test for detecting molecular signs of residual cancer after treatment.
The test is designed for solid tumours including breast, colorectal, lung, ovarian and pancreatic cancers.
It creates a tumour-specific fingerprint from roughly 50–100 mutations and later checks blood samples for that fingerprint.
MRD testing may detect microscopic disease earlier than imaging, but it is intended to complement—not replace—PET, CT and MRI scans.
The baseline test reportedly costs about Rs 40,000, while follow-up blood tests cost about Rs 20,000.
- Who
- MedGenome, a genomics-driven diagnostics and research services company.
- What
- The company launched OncoTrack MRD, a personalised, tumour-informed blood test to detect molecular signs of residual cancer after treatment.
- Where
- India is the market context described in the report; the article does not specify a launch location.
- Why
- To help doctors monitor residual disease, assess recurrence risk and track treatment response through repeatable blood testing.
- Test name
- OncoTrack MRD
- Technology
- Analysis of circulating tumour DNA and the patient’s original tumour using ultra-deep sequencing
- Cancer types
- Solid tumours including breast, colorectal, lung, ovarian and pancreatic cancers
- Personalised fingerprint
- Roughly 50–100 mutations identified from the patient’s original tumour
- Reported baseline price
- Around Rs 40,000
- Reported follow-up price
- Around Rs 20,000 per blood test
- India’s 2024 cancer burden
- An estimated 1.56 million new cases and 901,828 deaths, according to a World Health Organization–International Agency for Research on Cancer report